Reshaping Risk/Reward in Biotech VC
As returns from internet start-ups continue to reshape venture capital, the risk/reward ratios for biotech companies become less attractive for VC's. Since the biotechnology industry plays a direct role in improving health care, perhaps what's needed are investment incentives provided by public policy.
You may also be interested in...
Having achieved a turnaround in its R&D and commercial fortunes, AstraZeneca’s hopes the opening of a new research center will herald its next wave of novel therapies.
Pfizer and BioNTech’s Comirnaty supply under existing agreements will continue as planned despite anticipated expansion into a new child sub-population in Europe.
The value-based procurement scheme in China is about to be implemented on insulin products and while most of Novo Nordisk's therapies were included in the tender, price cuts are going to impact global sales growth by 3% next year.